Significant association of cutaneous adverse events with hydroxyurea: results from a prospective non-interventional study in BCR-ABL1-negative myeloproliferative neoplasms (MPN) - on behalf of the German Study Group-MPN

According to results of a non-interventional study, patients with BCL-ABL1-negative myeloproliferative neoplasms (MPNs) treated with hydroxyurea experienced a substantially higher incidence of cutaneous adverse events (54.1%), including ulcers, precancerous lesions, and skin cancer, compared with those receiving other MPN-related cytoreductive treatments (4.3%) such as ruxolitinib, anagrelide, and interferon alpha.